R&D and Innovation
Kang Shizhen Innovative Drug R&D System
R&D Philosophy
Guided by Patient Clinical Needs
Hubei Kang Shizhen Pharmaceutical Technology Co., Ltd. always adheres to patient clinical needs as the guide, focusing on technological innovation and product R&D in the field of tumor treatment, committed to developing safe, effective, and accessible anti-tumor drugs.
The company focuses on precision tumor treatment, prioritizing the layout of anti-tumor innovative drugs and related technology platform construction, actively exploring innovative R&D paths centered on paclitaxel anti-cancer drugs, while paying attention to frontier fields such as tumor immunotherapy, targeted therapy, and biological drugs.
Providing more treatment options for cancer patients, improving patient quality of life, and benefiting more families
Building Tumor Innovative Drug R&D Platform
围绕 tumor development mechanisms and precision treatment needs, building a future-oriented innovative drug R&D system
Kang Shizhen focuses on tumor development mechanisms and precision treatment needs, gradually building a future-oriented innovative drug R&D system, with emphasis on anti-tumor drug screening, efficacy evaluation, mechanism of action research, and new target exploration.
The company will actively develop the following research platforms:
Tumor Immunology Research Platform
Focusing on tumor immune mechanism research, exploring new immunotherapy strategies
Tumor Microenvironment Analysis & Immune Mechanism Platform
In-depth analysis of tumor microenvironment, revealing immune escape mechanisms
Novel Anti-Tumor Target Discovery & Validation Platform
Discovering and validating novel drug targets with clinical value
Cell-Level & Animal Model Efficacy Evaluation Platform
Establishing comprehensive in vitro and in vivo efficacy evaluation systems
By establishing a comprehensive in vitro and in vivo efficacy evaluation system, systematically validating candidate drugs, and accelerating anti-cancer drugs with potential therapeutic value into the R&D stage.
Advancing Biological Innovative Drug R&D
Actively following global biomedical development trends, conducting frontier exploration around precision tumor treatment technologies
In the future, the company will focus on three major directions:
Antibody & Targeted Biologic Drug R&D
- Multi-specific antibody technology
- Antibody-drug conjugate (ADC) technology
- Tumor targeted therapy drugs
- Novel immunomodulatory drugs
Tumor Immunotherapy Technology Research
- Tumor immune cell analysis platform
- Tumor immune function evaluation platform
- Novel immunotherapy target screening platform
mRNA & Novel Therapeutic Technology Exploration
- Tumor-associated antigen screening
- mRNA drug design
- Novel delivery system research
Strengthening Small Molecule Innovative Drug R&D
Building systematic R&D capabilities, focusing on frontier technologies
Systematic R&D Capabilities
- Anti-tumor small molecule drug design
- In vitro and in vivo efficacy screening
- Pharmacokinetics research (PK/PD)
- Drug safety evaluation
- Novel drug mechanism of action exploration
Frontier Technology Focus
Continuously following the latest technological advances in drug R&D, integrating frontier science and technology into the innovative drug R&D system.
Quality Assurance
Deepening High-Quality Anti-Tumor Drug R&D and Production
Relying on years of drug R&D and production experience, continuously strengthening pharmaceutical quality management system construction.
Key R&D Directions:
- Anti-tumor drugs with high clinical demand
- Drug varieties with high technical barriers
- Treatment solutions with high patient value
Exploring Complex Formulations & Innovative Treatment Solutions
Improving drug efficacy, reducing adverse reactions, optimizing administration methods, enhancing patient treatment experience
Improved Drug Efficacy
Optimizing drug formulations to enhance therapeutic effects
Reduced Adverse Reactions
Minimizing side effects and improving medication safety
Optimized Administration
Improving delivery routes and patient compliance
Enhanced Treatment Experience
Addressing patient needs and improving treatment comfort
Conducting complex formulation and改良型 innovative drug research, providing patients with better treatment options
Patient-Centered
Promoting medical translation and clinical value realization
Patient-centered, with a mission for life and health
Research Institutions
Strengthening academic exchange and cooperation
Medical Institutions
Advancing clinical research translation
Industry Partners
Building a complete innovation chain
Establishing a complete innovation chain from drug discovery, clinical research to product translation
In the future, Kang Shizhen will continue to focus on the anti-tumor field, persist in technological innovation, promote the R&D and launch of more high-value anti-cancer drugs,
bringing new hope to cancer patients and contributing to the cause of human life and health.